Evaluation of therapeutic effects of Crocin in patients with polycystic ovary syndrome: A randomized Double-Blind clinical trial.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY
Fatemeh Saghafi, Atiyeh Javaheri, Farhad Mohammadi, Nooshin Hatamizadeh, Fatemeh Khanizadeh, Mahdieh Safakish, Adeleh Sahebnasagh
{"title":"Evaluation of therapeutic effects of Crocin in patients with polycystic ovary syndrome: A randomized Double-Blind clinical trial.","authors":"Fatemeh Saghafi, Atiyeh Javaheri, Farhad Mohammadi, Nooshin Hatamizadeh, Fatemeh Khanizadeh, Mahdieh Safakish, Adeleh Sahebnasagh","doi":"10.1186/s40780-025-00432-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Polycystic ovary syndrome (PCOS) is the most common endocrine-metabolic disorder in women of reproductive age. Crocin is known as the main component of saffron, which has antioxidant properties and has the ability to scavenge free radicals. Considering the pathophysiology of PCOS and also the anti-inflammatory and antioxidant properties of crocin in improving insulin resistance, we aimed to evaluate the efficacy of the combination of crocin and metformin compared to metformin alone in PCOS patients.</p><p><strong>Methods: </strong>This study is a prospective, double-blind randomized controlled clinical trial. Fifty patients with PCOS and hirsutism were included from Baqaipour Obstetrics and Gynecology Clinic in Yazd and randomly assigned into the two study arms of control group [metformin and placebo (n = 25)] or intervention group [metformin and crocin (n = 25)]. Patients were administered crocin 15 mg tablets once a day in combination with metformin 500 mg twice a day for 12 weeks to complete three full periods of the monthly cycle. The studied endpoints were evaluated at the beginning and end of the study.</p><p><strong>Results: </strong>Crocin significantly improved the serum level of follicle-stimulating hormone (FSH) (P = 0.048) and Ferriman- Gallwey score (P = 0.042) at day 90. Furthermore, crocin group had a significant improvement in terms of acne severity at the end of the study (P = 0.03), so that none of the patients in the crocin group had severe acne at the end of the study. However, the comparisons between two groups were not statistically significant for other evaluated outcomes including fasting blood sugar (FBS), dihydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone (LH), dermatology life quality index (DLQI), and blood pressure (BP) at the end of the study.</p><p><strong>Conclusion: </strong>In the present study, concurrent use of crocin along with metformin was significantly effective in ameliorating the unpleasant side effects of PCOS, including hirsutism and acne, and increasing FSH sex hormone levels in patients with PCOS.</p><p><strong>Trial registry date: </strong>26/08/2021, Trial Registry number: IRCT20210730052027N1.</p>","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"11 1","pages":"69"},"PeriodicalIF":1.2000,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12333146/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-025-00432-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Polycystic ovary syndrome (PCOS) is the most common endocrine-metabolic disorder in women of reproductive age. Crocin is known as the main component of saffron, which has antioxidant properties and has the ability to scavenge free radicals. Considering the pathophysiology of PCOS and also the anti-inflammatory and antioxidant properties of crocin in improving insulin resistance, we aimed to evaluate the efficacy of the combination of crocin and metformin compared to metformin alone in PCOS patients.

Methods: This study is a prospective, double-blind randomized controlled clinical trial. Fifty patients with PCOS and hirsutism were included from Baqaipour Obstetrics and Gynecology Clinic in Yazd and randomly assigned into the two study arms of control group [metformin and placebo (n = 25)] or intervention group [metformin and crocin (n = 25)]. Patients were administered crocin 15 mg tablets once a day in combination with metformin 500 mg twice a day for 12 weeks to complete three full periods of the monthly cycle. The studied endpoints were evaluated at the beginning and end of the study.

Results: Crocin significantly improved the serum level of follicle-stimulating hormone (FSH) (P = 0.048) and Ferriman- Gallwey score (P = 0.042) at day 90. Furthermore, crocin group had a significant improvement in terms of acne severity at the end of the study (P = 0.03), so that none of the patients in the crocin group had severe acne at the end of the study. However, the comparisons between two groups were not statistically significant for other evaluated outcomes including fasting blood sugar (FBS), dihydroepiandrosterone-sulfate (DHEA-S), luteinizing hormone (LH), dermatology life quality index (DLQI), and blood pressure (BP) at the end of the study.

Conclusion: In the present study, concurrent use of crocin along with metformin was significantly effective in ameliorating the unpleasant side effects of PCOS, including hirsutism and acne, and increasing FSH sex hormone levels in patients with PCOS.

Trial registry date: 26/08/2021, Trial Registry number: IRCT20210730052027N1.

番红花素治疗多囊卵巢综合征疗效评价:一项随机双盲临床试验。
背景:多囊卵巢综合征(PCOS)是育龄妇女最常见的内分泌代谢疾病。藏红花素被认为是藏红花的主要成分,它具有抗氧化特性,并具有清除自由基的能力。考虑到多囊卵巢综合征的病理生理,以及藏红花素在改善胰岛素抵抗中的抗炎和抗氧化作用,我们旨在评估藏红花素与二甲双胍联合治疗多囊卵巢综合征患者的疗效,并与单用二甲双胍进行比较。方法:本研究为前瞻性、双盲、随机对照临床试验。选取亚兹德市巴盖泊妇产医院的PCOS合并多毛症患者50例,随机分为对照组[二甲双胍+安慰剂组(n = 25)]和干预组[二甲双胍+西红花素组(n = 25)]两组。患者服用藏红花素15毫克片,每天1次,联合二甲双胍500毫克,每天2次,持续12周,以完成三个完整的月周期。在研究开始和结束时对研究终点进行评估。结果:藏红花素显著提高第90天血清促卵泡激素(FSH)水平(P = 0.048)和Ferriman- Gallwey评分(P = 0.042)。此外,在研究结束时,藏红花素组在痤疮严重程度方面有显著改善(P = 0.03),因此在研究结束时,藏红花素组中没有患者出现严重的痤疮。然而,两组之间的其他评估结果比较无统计学意义,包括空腹血糖(FBS)、硫酸二氢表雄酮(DHEA-S)、黄体生成素(LH)、皮肤病生活质量指数(DLQI)和研究结束时的血压(BP)。结论:在本研究中,西红花素联合二甲双胍可显著改善PCOS患者多毛、痤疮等不良反应,并可提高PCOS患者FSH性激素水平。试验注册日期:26/08/2021,试验注册号:IRCT20210730052027N1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.80
自引率
0.00%
发文量
29
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信